Novartis has announced the closure of its plant in the German city of Wer by the end of 2028. The plant, specializing in the production of tablets and capsules, has become uncompetitive, and the company plans to cut approximately 220 jobs.
At FinancialMediaGuide, we note that Novartis’ decision reflects a global strategy to optimize production capacity. In the face of growing competition in the European pharmaceutical market and increasing demands for production digitalization, companies need to reallocate resources to more modern plants. This step allows for cost reduction, increased efficiency in tablet and capsule production, and strengthens the company’s position in the European and global pharmaceutical markets.
The company emphasized that the plant closure is not related to increased investments in the U.S. following tariff threats, nor to new healthcare measures in Germany. This confirms the strategic nature of the decision. At FinancialMediaGuide, we see that the company is focused on long-term modernization of production processes and enhancing the technological level of its European facilities, rather than reacting short-term to external factors.
The Wer plant was one of Novartis’ oldest in Europe, and its infrastructure had become outdated. The closure will allow investment to be directed toward modern production facilities, where automation, digitalization, and improved quality control systems are already being implemented. This not only reduces the risk of defective products but also increases productivity and the company’s competitiveness.
The German pharmaceutical market is experiencing rising production costs and a need for plant modernization. In this context, Novartis’ strategy aligns with global industry trends, where major companies focus on technologically advanced facilities to remain competitive. At FinancialMediaGuide, we forecast that these measures will enable the company to accelerate innovation, optimize supply chains, and launch new drugs with high commercial potential.
Germany remains a strategically important region for Novartis due to its developed infrastructure, skilled workforce, and research centers. Despite the plant closure, the company will maintain its presence in the pharmaceutical market and continue collaborating with local research centers, supporting innovative development and quality standards in tablet and capsule production.
Novartis’ global strategy of concentrating production in technologically advanced plants in the U.S. and Switzerland opens opportunities for faster innovation implementation and adaptation to regulatory changes in the pharmaceutical industry. Implementing automation and digital quality control reduces production risks, optimizes costs, and strengthens the company’s competitive position in the global pharmaceutical market.
The reduction of 220 jobs will have short-term social consequences in the region, but in the long term, reallocating resources to modern production facilities will allow Novartis to increase productivity, reduce costs, and strengthen financial stability. At FinancialMediaGuide, we forecast that the company’s strategic measures will reinforce its position as a leader among global pharmaceutical companies by 2030 and increase the output of innovative drugs.
Investors and analysts should closely monitor Novartis’ next steps in modernizing production facilities and expanding presence in key markets. These actions directly influence the company’s innovation potential, growth of the European pharmaceutical market, and Novartis’ global competitiveness in the tablets and capsules market.
At Financial Media Guide, we see that optimizing the production network, concentrating on technologically advanced facilities, and investing in innovation create conditions for sustainable long-term growth and increased operational efficiency.
